Augustine Therapeutics
6 known investors
Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS. Founded as a spin-off from VIB and KU Leuven, it focuses on drug development for currently untreatable complex neurological diseases.
Investors · 6
Competitors · 2
by search overlapBioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Walgreens3 shared keywordsWalgreens operates a pharmacy and retail health and wellness business, offering prescription services, over-the-counter medications, health products, and photo services to consumers.
Companies competing with Augustine Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Augustine Therapeutics do?
- Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS. Founded as a spin-off from VIB and KU Leuven, it focuses on drug development for currently untreatable complex neurological diseases.
- Who are Augustine Therapeutics's investors?
- Augustine Therapeutics's investors include AdBio partners, Jeito Capital, Novo Holdings, PMV, V-Bio Ventures, Asabys Partners.